Updated Findings With Ruxolitinib in Polycythemia Vera
Jean-Jacques Kiladjian, MD, PhD, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera still remained on treatment with ruxolitinib.
Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology at Paris Diderot University, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera (PV) still remained on treatment with ruxolitinib (Jakafi).
In addition, more than 74% of patients who achieved a primary response maintained this response, Kiladjian says. Of the patients who achieved a complete hematologic response, 54% maintained that response as well.
Kiladjian says he was pleased to see that molecular response was achieved in these patients as the meanJAK2
Degree of Anemia Influences Therapy for Myelofibrosis
January 23rd 2025During a Case-Based Roundtable® event, Andrew Kuykendall, MD, and participants discussed the the importance of early intervention and consideration of anemia with JAK inhibitor therapy for patients with myelofibrosis in the first article of a 2-part series.
Read More
